B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Information about B-ALL and CAR-T cell therapy evaluation
The information on this page is for general informational purposes. Whether CAR-T therapy is suitable for a specific patient is determined only through specialist physician evaluation. This page does not constitute medical advice.
What is B-ALL?
B-cell acute lymphoblastic leukemia is a blood disease that starts in the bone marrow. The bone marrow is the tissue where blood cells are produced. In B-ALL, immature lymphoid cells can proliferate uncontrollably; this condition can affect the production of healthy blood cells and normal immune functions.
The term "acute" describes the disease's potential for rapid progression. B-ALL can be seen in children and adults. Age, biological characteristics of the disease, response to treatment and previous treatment history are determining factors in the treatment plan.
What are the symptoms?
B-ALL can present with different symptoms due to the decrease in healthy blood cells. Symptoms can also be caused by other diseases; definitive evaluation is made by a physician.
Persistent fatigue, weakness or paleness
Frequent or prolonged infections
Fever
Easy bruising, nose/gingival bleeding or pinpoint bleeding on the skin
Bone or joint pain
Loss of appetite or weight loss
Lymph node swelling in the neck, armpit or groin
Feeling of fullness in the abdominal area
Emergency warning: Fever, active bleeding, significant shortness of breath, altered consciousness or rapid deterioration in general condition may require emergency medical evaluation. In such cases, the nearest emergency health facility should be consulted.
Diagnosis and disease evaluation
Bone marrow examination, blood tests, flow cytometry, cytogenetic and molecular tests may be used in the diagnosis and monitoring of treatment response in B-ALL. Physicians evaluate this information together to understand the characteristics and risk profile of the disease.
Diagnosis and bone marrow reports
Flow cytometry results
Cytogenetic and molecular tests
Minimal residual disease (MRD) evaluations, if available
Applied treatments and treatment response
Infection, organ functions and general clinical status
Treatment approach
B-ALL treatment usually consists of multiple phases and may differ according to child/adolescent/adult patients.
The treatment plan is determined by the specialist hematology team according to the biology of the disease, age, risk group, response to previous treatments and the patient's general condition. In selected patients, the treatment plan may include evaluation of chemotherapy, targeted or immunotherapies, stem cell transplantation and CAR-T cell therapy.
When can CAR-T cell therapy be evaluated?
CAR-T cell therapy can be taken into evaluation especially in some B-ALL cases where the disease has recurred or has not responded sufficiently to standard treatments. The timing of this decision is important; the current status of the disease, treatment-related effects and the patient's general clinical stability are evaluated together.
Has the disease recurred or is it resistant to treatment?
What treatments were applied?
Is the laboratory information required for the evaluation of target antigens available?
What is the patient's infection status, organ functions and performance?
Is an additional approach needed for disease control before treatment?
Important: The decision process in pediatric patients should be conducted together with pediatric hematology, team with cell therapy experience and family. The expected benefits, possible risks, need for close monitoring and alternative options of the treatment should be clearly discussed.
Note: CAR-T evaluation can be on the agenda in both child and adult age groups in appropriate patients. However, separate specialist evaluation is required for each age group and each clinical situation.
Documents for evaluation
The following documents should be prepared for the eligibility evaluation:
- Current physician summary and epicrisis
- Diagnosis and follow-up bone marrow reports
- Flow cytometry, cytogenetic and molecular test results
- conditions.ball.doc_cytogenetics
- MRD results, if available
- Applied treatment protocols, dates and response information
- Recent blood tests, liver and kidney functions
- Infection evaluation and current medication list
- Current medication list
- Height-weight, age and relevant pediatric hematology notes in pediatric patients
Frequently Asked Questions
No. CAR-T evaluation can come to the agenda in both child or adult age groups in appropriate patients. However, separate specialist evaluation is required for each age group and each clinical situation.
No. Treatment selection varies according to the characteristics of the disease, previous treatments, the patient's clinical status and available options. This decision can only be made by the specialist team.
It is important to ask the treatment team about the current status of the disease, the purpose of treatment, possible benefits and risks, alternative options, need for hospitalization/monitoring and daily life planning.
Request an eligibility evaluation
Your medical documents are reviewed by our specialist team. Your application does not constitute a commitment to treatment; individual and multidisciplinary evaluation is required for each patient.